DMEMEDS shared post via Reuters: Bristol immunotherapy prolongs survival in melanoma trial

(Reuters) - A late stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/-dgHUvLcT14/story01.htm

Read More